Valuation: Xencor, Inc.

Market Cap 1.22B 1.07B 988M 913M 1.73B 117B 1.77B 11.88B 4.62B 57.18B 4.58B 4.48B 199B P/E 2026 *
-4.23x
P/E 2027 * -5.11x
Enterprise Value 1.22B 1.07B 988M 913M 1.73B 117B 1.77B 11.88B 4.62B 57.18B 4.58B 4.48B 199B EV / Sales 2026 *
17.3x
EV / Sales 2027 * 11x
Free-Float
98.82%
Yield 2026 *
-
Yield 2027 * -
1 day+5.04%
1 week+7.02%
Current month+2.24%
1 month+44.26%
3 months+34.37%
6 months+16.00%
Current year+7.51%
1 week 14.61
Extreme 14.61
16.51
1 month 11.56
Extreme 11.56
16.8
Current year 10.38
Extreme 10.375
16.8
1 year 6.92
Extreme 6.92
18.69
3 years 6.92
Extreme 6.92
27.24
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 31/01/2005
Director of Finance/CFO 48 08/04/2024
Chief Tech/Sci/R&D Officer 61 30/09/2006
Director TitleAgeSince
Director/Board Member 55 31/07/1997
Director/Board Member 58 24/07/2014
Director/Board Member 72 17/03/2015
Date Insider Type Main position Quantity % Market Cap.
06-17Sell

Director

-6,843 0.0092%
06-14Sell

Director

-7,527 0.0102%
06-14Sell

Director

-5,064 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
+5.04%+7.02%+99.03%-29.63% 1.22B
-0.80%-3.85%+70.62%+125.65% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+3.27%+8.91%+21.21%+486.76% 25.26B
-0.81%-0.42%-16.24%-12.47% 23.65B
+3.93%+3.35%+43.09%-2.47% 18.69B
-0.38%+0.51%+37.33%-26.28% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-0.92%+1.58%+35.79% - 14.26B
-1.70%+3.98%+28.96%+190.57% 14.1B
Average +0.75%+3.35%+60.77%+132.92% 24.06B
Weighted average by Cap. -0.13%+2.17%+57.80%+142.59%

Financials

2026 *2027 *
Net sales 70.58M 61.91M 57.15M 52.81M 100M 6.76B 102M 687M 267M 3.31B 265M 259M 11.48B 110M 96.87M 89.43M 82.65M 157M 10.58B 160M 1.08B 418M 5.18B 415M 406M 17.97B
Net income -309M -271M -251M -232M -439M -29.63B -448M -3.01B -1.17B -14.5B -1.16B -1.14B -50.34B -288M -253M -233M -215M -408M -27.57B -417M -2.8B -1.09B -13.49B -1.08B -1.06B -46.83B
Net Debt - -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
08/07/26 US$16.46 +5.04% 1,164,151
07/07/26 US$15.67 +5.24% 719,118
06/07/26 US$14.89 -0.73% 504,887
02/07/26 US$15.00 -2.47% 919,419
01/07/26 US$15.38 -4.47% 1,020,105
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
16.46USD
Average target price
28.33USD
Spread / Average Target
+72.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock